BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30377737)

  • 41. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
    Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
    Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noninferiority of
    Dai D; Rollo FD; Bryant J; Kim EE
    Contrast Media Mol Imaging; 2018; 2018():8969714. PubMed ID: 29736155
    [No Abstract]   [Full Text] [Related]  

  • 44. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.
    Chin R; McCain TW; Miller AA; Dunagan DP; Acostamadiedo J; Douglas Case L; Harkness BA; Adler LP; Haponik EF
    Lung Cancer; 2002 Jul; 37(1):1-6. PubMed ID: 12057859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
    Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
    Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity.
    Hu M; Han A; Xing L; Yang W; Fu Z; Huang C; Zhang P; Kong L; Yu J
    Clin Nucl Med; 2011 Jun; 36(6):429-33. PubMed ID: 21552018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. F-18 fluorodeoxyglucose PET/CT findings in active hiccups.
    Yeatman CF; Minoshima S
    Clin Nucl Med; 2009 Mar; 34(3):197-8. PubMed ID: 19352293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy.
    Huang W; Liu B; Fan M; Zhou T; Fu Z; Zhang Z; Li H; Li B
    Eur J Radiol; 2015 Mar; 84(3):482-488. PubMed ID: 25533718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
    Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
    Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical values of (18) F-FDG PET/CT in oral cavity cancer with dental artifacts on CT or MRI.
    Hong HR; Jin S; Koo HJ; Roh JL; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2014 Nov; 110(6):696-701. PubMed ID: 24995957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.